Insmed

INSMApproved

Insmed is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform lives of patients facing serious diseases. The company has achieved commercial success with approved therapies in the US and EU, while advancing multiple programs through clinical development. Insmed has been consistently recognized as Science magazine's #1 Top Biopharma Employer for five consecutive years and maintains a culture of collaboration and innovation across 9 corporate offices worldwide.

Market Cap

$29.3B

Employees

1,500+

Focus

Drug DeliverySmall Molecules

INSM · Stock Price

USD 136.00+113.97 (+517.34%)

Historical price data

AI Company Overview

Technology Platform

Insmed leverages synergistic platforms and multiple technologies in parallel to maximize impact and accelerate discovery, with collaborative ecosystems enabling cross-pollination of ideas and diverse therapeutic modalities.

Pipeline Snapshot

48 drugs in pipeline, 15 in Phase 3

Drug	Indication	Stage
Liposomal amikacin for inhalation	Cystic Fibrosis	Phase 3
Treprostinil Palmitil Inhalation Powder + Placebo	Pulmonary Arterial Hypertension	Phase 3
Brensocatib + Placebo	Covid19	Phase 3
ALIS + Azithromycin + Ethambutol + ELC (matching placebo for ALIS)	Mycobacterium Infections, Nontuberculous	Phase 3
Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFl...	Pseudomonas Aeruginosa Infection	Phase 3

Funding History

Total raised: $360M

Debt$225MUndisclosedJun 15, 2017

PIPE$75MUndisclosedMar 15, 2007

IPO$60MUndisclosedJun 15, 2000

FDA Approved Drugs

BRINSUPRINDAAug 12, 2025

ARIKAYCE KITNDASep 28, 2018

Opportunities

Insmed has significant growth opportunities through its diverse pipeline advancing through clinical development, recent commercial successes in both US and EU markets, and expansion into new therapeutic areas.

The company's strong culture and global presence position it well for continued innovation and market expansion.

Risk Factors

Key risks include clinical development uncertainties inherent in biopharmaceutical companies, increasing competition in the rare disease space, and potential regulatory challenges that could impact development timelines.

Market access and reimbursement challenges for rare disease therapies also present ongoing risks.

Competitive Landscape

Insmed competes in the rare disease and respiratory therapeutics space against established pharmaceutical companies and emerging biotechs. The company differentiates through its patient-centric approach, proven commercialization track record, and comprehensive global development capabilities, while its consistent recognition as a top employer provides talent acquisition advantages.

Publications

Patents

Pipeline

FDA Approvals